140P - Metabolic Syndrome and Inflammation in Castration Resistant Prostate Cancer (CRPC) patients (pts) treated with Abiraterone (abi) and Enzalutamide (...

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Cytotoxic agents
Cancers in Adolescents and Young Adults (AYA)
Prostate Cancer
Genitourinary Cancers
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Biological therapy
Presenter Vincenza Conteduca
Citation Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363
Authors V. Conteduca1, O. Caffo2, L. Galli3, A. Maugeri4, E. Scarpi5, F. Maines2, V. Chiuri6, C. Lolli1, S. Kinspergher2, G. Schepisi1, M. Santoni7, D. Santini8, L. Fratino9, S.L. Burgio1, S. Salvi10, C. Menna1, U. De Giorgi1
  • 1Department Of Oncology, Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT
  • 2Department Of Oncology, Ospedale Santa Chiara, 38122 - Trento/IT
  • 3Oncology, Azienda Ospedaliero-Universitaria Pisana Istituto Toscano Tumori, Pisa/IT
  • 4Oncology Pharmacy, Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT
  • 5Biostatistics And Clinical Trials, Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT
  • 6Department Of Oncology, Ospedale Vito Fazzi, 73100 - Lecce/IT
  • 7Department Of Oncology, AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, 60126 - Ancona/IT
  • 8Department Of Oncology, Campus Bio-Medico di Roma, 128 - Roma/IT
  • 9Medical Oncology Department, Centro di Riferimento Oncologico di Aviano, 33081 - Aviano/IT
  • 10Biosciences Laboratory, Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT



Metabolic syndrome (MS) and inflammation (INF) alterations are hallmarks of cancer progression. The study aimed to firstly assess the relationship between MS and INF and its impact on progression-free/overall survival (PFS/OS) in CRPC pts.


We retrospectively evaluated CRPC pts treated with abi and enza in 7 Italian Institutes between March 2011 and October 2016. MS was defined by modified Adult Treatment Panel III criteria, and INF characterized by the presence of at least 1 of these criteria: NLR≥3, elevated VES or C-reactive protein (CRP) levels.


Eighty-three of 551 pts evaluated (15%) met MS criteria at baseline, whereas for 40 (8.5%) this occurred during treatment. No significant difference of MS incidence and cardiometabolic toxicities were reported between abi or enza. Pts with MS (MS+) showed a greater INF profile compared to MS- (79% vs 28%, p 


The presence of MS is strongly associated with INF. Pre-treatment identification of MS and INF alterations may represent an available and easy to perform tool for a better prognostication of CRPC pts treated with abi or enza. A prospective evaluation is warranted.

Clinical trial identification


Legal entity responsible for the study

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl – IRCCS




V. Conteduca, U. De Giorgi: Speaker honoraria or travel support from Astellas, Janssen-Cilag and Sanofi- Aventis. All other authors have declared no conflicts of interest.